New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations

Journal of Medicinal Chemistry

Volumn 51, Issue 3, 2008, Pages 689-693

  Moulin, Aline ^a   Demange, Luc ^a   Ryan, Joanne ^a   Mousseaux, Delphine ^a   Sanchez, Pierre ^a   Bergé, Gilbert ^a   Gagne, Didier ^a   Perrissoud, Daniel ^b   Locatelli, Vittorio ^c   Torsello, Antonio ^c   Galleyrand, Jean Claude ^a   Fehrentz, Jean Alaín ^a   Martinez, Jean ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b Zentaris GmbH   (Germany)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; [1 [4 (2,4 DIMETHOXYBENZYL) 5 PHENETHYL 4H 1,2,4 TRIAZOL 3 YL] 2 (1H INDOL 3 YL)ETHYL]PICOLINAMIDE; [1 [5 [2 (1H INDOL 3 YL)ETHYL] 4 (2,4 DIMETHOXYBENZYL) 4H 1,2,4 TRIAZOL 3 YL] 2 (1H INDOL 3 YL)ETHYL]PYRAZINE 2 CARBOXAMIDE; ALPHA AMINOISOBUTYRYL DERIVATIVE; AROMATIC COMPOUND; FUNCTIONAL GROUP; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR ANTAGONIST; HETEROCYCLIC COMPOUND; HEXARELIN; PHENYL GROUP; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FOOD INTAKE; GROWTH HORMONE RELEASE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTI-OBESITY AGENTS; EATING; GROWTH HORMONE; HUMANS; LLC-PK1 CELLS; OLIGOPEPTIDES; PICOLINES; PYRAZINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, GHRELIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; TRIAZOLES;

EID: 39149128278     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701292s     Document Type: Article

References (17)

1. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402, 656-660.
2. Howard, A. D.; Feighner, S. D.; Cully, D. F.; Arena, J. P.; Liberator, P. A.; Rosenblum, C. I.; Hamelin, M. J.; Hreniuk, D. L.; Palyha, O. C.; Anderson, J.; Paress, P. S.; Diaz, C.; Chou, M.; Liu, K.; Mckee, K. K.; Pong, S. S.; Chaung, L. Y.; Elbrecht, A.; Heavens, R.; Rigby, M.; Sirinathsinghji, D. J. S.; Dean, D. C.; Melillo, D. G.; Patchett, A. A.; Nargund, R.; Griffin, P. R.; DeMartino, J. A.; Gupta, S. K.; Schaeffer, J. M.; Smith, R. G.; Van Der Ploeg, L. H. T. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273, 974-977.
3. Kojima, M.; Jangawa, K. Ghrelin: structure and function. Physiol. Rev. 2005, 85, 495-522.
4. Van der Lely, A. J.; Tschop, M.; Herman, M. L.; Ghigo, E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 2004, 25 (3), 426-457.
5. Nakazato, M.; Murakami, N.; Date, Y.; Kojima, M.; Matsuo, H.; Kangawa, K.; Matsukura, S. A role for ghrelin in the central regulation of feeding. Nature 2001, 409, 194-198.
6. Asakawa, A.; Inui, A.; Kaga, T.; Katsuura, G.; Fujimiya, M.; Fujin, M. A.; Kasuga, M. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003, 52, 947-952.
7. Xin, Z.; Serby, M. D.; Zhao, H.; Kosogof, C.; Szczepankiewicz, B. G.; Liu, M.; Liu, B.; Hutchins, C. W.; Sarris, K. A.; Hoff, E. D.; Falls, H. D.; Lin, C. W.; Ogiela, C. A.; Collins, C. A.; Brune, M. E.; Bush, E. N.; Droz, B. A.; Fey, T. A.; Knourek-Segel, V. E.; Shapiro, R.; Jacobson, P. B.; Beno, D. W. A.; Turner, T. M.; Sham, H. L.; Liu, G. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J. Med. Chem. 2006, 49, 4459-4469.
8. Serby, M. D.; Zhao, H.; Szczepankiewicz, B. G.; Kosogof, C.; Xin, Z.; Liu, B.; Liu, M.; Nelson, L. T. J.; Kaszubska, W.; Falls, H. D.; Schaefer, V.; Bush, E. N.; Shapiro, R.; Droz, B. A.; Knourek-Segel, V. E.; Fey, T. A.; Brune, M. E.; Beno, D. W. A.; Turner, T. M.; Collins, C. A.; Jacobson, P. B.; Sham, H. L.; Liu, G. 2,4-Diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J. Med. Chem. 2006, 49, 2568-2578.
9. Rudolph, J.; Esler, W. P.; O'Connor, S.; Coish, P. D. G.; Wickens, P. L.; Brands, M.; Bierer, D. E.; Bloomquist, B. T.; Bondar, G.; Chen, L.; Chuang, C.-Y.; Claus, T. H.; Fathi, Z.; Fu, W.; Khire, U. R.; Kristie, J. A.; Liu, X.-G.; Lowe, D. B.; McClure, A. C.; Michels, M.; Ortiz, P. D.; Ramsden, R. W.; Schoenleber, T. E.; Shelekhin, A.; Vakalopoulos, W.; Tang, L.; Wang, A. A.; Yi, L.; Gardell, S. J.; Livingston, J. N.; Sweet, L. J.; Bullock, W. H. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J. Med. Chem. 2007, 50, 5202-5216.
10. Demange, L.; Boeglin, D.; Moulin, A.; Mousseaux, D.; Ryan, J.; Bergé, G.; Gagne, D.; Heitz, A.; Perrissoud, D.; Locatelli, V.; Torsello, A.; Galleyrand, J.-C.; Fehrentz, J.-A.; Martinez, J. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1. J. Med. Chem. 2007, 50, 1939-1957.
11. Moulin, A.; Demange, L.; Bergé, G.; Gagne, D.; Ryan, J.; Mousseaux, D.; Heitz, A.; Perrissoud, D.; Locatelli, V.; Torsello, A.; Galleyrand, J.-C.; Fehrentz, J.-A.; Martinez, J. Towards potent GHS-R1a ligands based on trisubstituted 1,2,4-triazole structure, synthesis and pharmacological in vitro and in vivo evaluations. 2. J. Med. Chem. 2007, 50, 5790-5806.
12. Guerlavais, V.; Boeglin, D.; Mousseaux, D.; Oiry, C.; Heitz, A.; Deghenghi, R.; Locatelli, V.; Torsello, A.; Ghe, C.; Catapano, F.; Muccioli, G.; Galleyrand, J. C.; Fehrentz, J. A.; Martinez, J. New active series of growth hormone secretagogues. J. Med. Chem. 2003, 46, 1191-1203.
13. Broglio, F.; Boutignon, F.; Benso, A.; Gottero, C.; Prodam, F.; Arvat, E.; Ghe, C.; Catapano, F.; Torsello, A.; Locatelli, V.; Muccioli, G.; Boeglin, D.; Guerlavais, V.; Fehrentz, J. A.; Martinez, J.; Ghigo, E.; Deghenghi, R. EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. J. Endocrinol. Invest. 2002, 25 (8), RC26-RC28.
14. Piccoli, F.; Degen, L.; MacLean, C.; Peter, S.; Baselgia, L.; Larsen, F.; Beglinger, C.; Drewe, J. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J. Clin. Endocrinol. Metab. 2007, DOI 10.1210/jc.2006-2160.
15. Boeglin, D.; Cantel, S.; Heitz, A.; Martinez, J.; Fehrentz, J.-A. Solution and solid-supported synthesis of 3,4,5-trisubstituted 1,2,4-triazole-based peptidomimetics. Org. Lett. 2003, 5, 4465-4468.
16. Holst, B.; Holliday, N. D.; Bach, A.; Elling, C. E.; Cox, H. M.; Schwartz, T. W. Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem. 2004, 53806-53817.
17. Holst, B.; Mokrosinski, J.; Lang, M.; Brandt, E.; Nygaard, R.; Frimurer, T. M.; Beck-Sickinger, A.; Schwartz, T. W. Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J. Biol. Chem. 2007, 282, 15799-15811.